Bioventus Inc. logo

Bioventus Inc. (BVS)

Market Closed
30 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
6. 62
-0.15
-2.22%
$
449.24M Market Cap
- P/E Ratio
0% Div Yield
585,200 Volume
- Eps
$ 6.77
Previous Close
Day Range
6.52 6.8
Year Range
5.47 14.38
Want to track BVS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.

Seekingalpha | 1 month ago
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 1 month ago
Bioventus Reports First Quarter Financial Results

Bioventus Reports First Quarter Financial Results

DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.

Globenewswire | 1 month ago
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025.

Globenewswire | 2 months ago
4 Healthcare Stocks to Buy as the Sector Faces Government Heat

4 Healthcare Stocks to Buy as the Sector Faces Government Heat

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Zacks | 2 months ago
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks | 3 months ago
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 3 months ago
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Seekingalpha | 3 months ago
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.

Benzinga | 3 months ago
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 3 months ago
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2024, and provided its financial guidance for full-year 2025.

Globenewswire | 3 months ago
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Globenewswire | 4 months ago
Loading...
Load More